Sp123
BEYOND GWAS: INSIGHTS INTO THE GENETIC ARCHITECTURE OF IBD IN DIVERSE POPULATIONS
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
The burden of IBD is rising globally. This session aims to understand the role of genetics in the development of IBD in diverse populations and define the pre-disease state in IBD. It will also explore the emerging field of multi-omics to clinically characterize IBD.
The burden of IBD is rising globally. This session aims to understand the role of genetics in the development of IBD in diverse populations and define the pre-disease state in IBD. It will also explore the emerging field of multi-omics to clinically characterize IBD.
Presenter
Icahn School of Medicine at Mount Sinai
Tracks
Related Products
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
APPLYING MACHINE LEARNING TO BIOLOGICAL DATA FOR PRECISION THERAPY IN IBD
Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
